High Serum CA19-9 Concentration Predicts Poor Prognosis in Elderly Patients with Stage IV Colorectal Cancer.
Carbohydrate antigen 19-9
Elderly patient
Stage IV colorectal cancer
Journal
Gastrointestinal tumors
ISSN: 2296-3774
Titre abrégé: Gastrointest Tumors
Pays: Switzerland
ID NLM: 101644585
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
19
06
2018
accepted:
17
09
2018
entrez:
13
4
2019
pubmed:
13
4
2019
medline:
13
4
2019
Statut:
ppublish
Résumé
The optimal treatment strategy for elderly patients with stage IV colorectal cancer (CRC) remains controversial due to limited research data. The purpose of this study was to evaluate treatment results and to clarify the prognostic factors, especially poor prognosis factors, in elderly patients with stage IV CRC. We retrospectively reviewed the data of 82 elderly patients (aged ≥75 years) with stage IV CRC who underwent surgical treatment at our hospital between April 2001 and March 2017. Factors that affected prognosis and the ability to undergo treatment were analyzed via multivariate analysis. The median overall survival (OS) in the patients with high pretreatment serum carbohydrate antigen 19-9 (CA19-9) concentration (> 370 U/mL) was significantly worse than in those with lower serum CA19-9 concentration (0-370 U/mL) (8.5 vs. 19.2 months, A high pretreatment serum CA19-9 concentration (> 370 U/mL) was a reliable predictive factor for poor prognosis, and aggressive treatments should be performed carefully in these patients. Moreover, various treatments, including surgery and chemotherapy, might improve OS in elderly patients with stage IV CRC.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
The optimal treatment strategy for elderly patients with stage IV colorectal cancer (CRC) remains controversial due to limited research data. The purpose of this study was to evaluate treatment results and to clarify the prognostic factors, especially poor prognosis factors, in elderly patients with stage IV CRC.
METHODS
METHODS
We retrospectively reviewed the data of 82 elderly patients (aged ≥75 years) with stage IV CRC who underwent surgical treatment at our hospital between April 2001 and March 2017. Factors that affected prognosis and the ability to undergo treatment were analyzed via multivariate analysis.
RESULTS
RESULTS
The median overall survival (OS) in the patients with high pretreatment serum carbohydrate antigen 19-9 (CA19-9) concentration (> 370 U/mL) was significantly worse than in those with lower serum CA19-9 concentration (0-370 U/mL) (8.5 vs. 19.2 months,
CONCLUSIONS
CONCLUSIONS
A high pretreatment serum CA19-9 concentration (> 370 U/mL) was a reliable predictive factor for poor prognosis, and aggressive treatments should be performed carefully in these patients. Moreover, various treatments, including surgery and chemotherapy, might improve OS in elderly patients with stage IV CRC.
Identifiants
pubmed: 30976583
doi: 10.1159/000493793
pii: gat-0005-0117
pmc: PMC6422141
doi:
Types de publication
Journal Article
Langues
eng
Pagination
117-124Références
World J Gastroenterol. 2015 May 7;21(17):5158-66
pubmed: 25954089
CA Cancer J Clin. 2014 Mar-Apr;64(2):104-17
pubmed: 24639052
World J Surg. 2008 Jun;32(6):1130-7
pubmed: 18340483
Med Oncol. 2016 Nov;33(11):121
pubmed: 27722895
J Thorac Cardiovasc Surg. 1999 Dec;118(6):1090-6
pubmed: 10595983
ANZ J Surg. 2015 Nov;85(11):815-22
pubmed: 26073054
Ann Coloproctol. 2017 Aug;33(4):134-138
pubmed: 28932722
Oncotarget. 2017 Sep 6;8(45):80002-80011
pubmed: 29108382
Colorectal Dis. 2015 May;17(5):417-25
pubmed: 25512077
PLoS One. 2017 Nov 15;12(11):e0188139
pubmed: 29141049
Eur J Cancer. 2017 Aug;81:90-101
pubmed: 28622612
J Cancer Res Clin Oncol. 2014 Mar;140(3):435-41
pubmed: 24414039
Cancer. 1998 Sep 15;83(6):1086-93
pubmed: 9740072
J Surg Res. 2016 Oct;205(2):384-392
pubmed: 27664887
Ann Surg Oncol. 2011 Nov;18(12):3252-60
pubmed: 21822557
J Clin Oncol. 2004 Sep 1;22(17):3475-84
pubmed: 15337795
Int J Cancer. 2016 Nov 1;139(9):2082-94
pubmed: 27342618
Asian Pac J Cancer Prev. 2011;12(5):1251-6
pubmed: 21875276
Ann Oncol. 2016 Jan;27(1):121-7
pubmed: 26487578
Hell J Nucl Med. 2017 Jan-Apr;20(1):41-45
pubmed: 28315907
Int J Surg. 2018 Apr;52:141-148
pubmed: 29486244
J Anus Rectum Colon. 2018 Mar 9;2(1):16-24
pubmed: 31583318
Clin Colorectal Cancer. 2016 Dec;15(4):e157-e163
pubmed: 27245559
Dis Colon Rectum. 2009 Apr;52(4):583-90; discussion 590-1
pubmed: 19404056
Korean J Intern Med. 2018 Nov;33(6):1182-1193
pubmed: 29166760
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Int J Clin Oncol. 2018 Feb;23(1):1-34
pubmed: 28349281